




PHARMACEUTICAL 2023

Seres Therapeutics Inc.
Rank 350 of 446





RealRate

PHARMACEUTICAL 2023

Seres Therapeutics Inc.
Rank 350 of 446



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Seres Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -67%, being 111% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	194,764
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	85,596
Liabilities, Non-Current	109,384
Other Assets	131,035
Other Compr. Net Income	48
Other Expenses	1,004
Other Liabilities	143,021
Other Net Income	-3,667
Other Revenues	7,128
Property and Equipment	22,985
Research and Development	172,920
Selling, General and Administrative Expense	79,694

Output Variable	Value in 1000 USD
Assets	348,784
Liabilities	338,001
Expenses	253,618
Revenues	7,128
Stockholders Equity	10,783
Net Income	-250,157
Comprehensive Net Income	-250,133
Economic Capital Ratio	-67%